GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-06. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The target of their operation was Ibrahim Dondou Chefou, who had attended a high-level meeting of regional leaders from the Islamic State in the Greater Sahara (ISGS) days earlier. After searching a deserted campsite and speaking with elders from the village of Tongo Tongo, seeking intelligence on the terrorist operative, they began a 110 miles (180 km) drive back to base. Travelling in mostly unarmored pick-up trucks, they were ambushed by around 50 ISGS terrorists. During the engagement, four Green Berets were killed and two were wounded, and five Nigeriens were killed and eight wounded. Twenty-one terrorists were killed.
Hydrogel dressings can adhere directly to the wound bed under normal physiological conditions via oxidation-reduction reactions of quinones. The adhesive properties of hydrogels have been shown to be enhanced by addition of positively charged microgels (MR) into the 3D matrix to increase electrostatic and hydrophobic interactions.
== Treatment == Treatment is normally azithromycin by oral tablets, or less commonly by a course of other antibiotics, such as benzathine benzylpenicillin, an alternative for patients where azithromycin treatment failed, or tetracycline tablets. Penicillin has been the front-line treatment since at least the 1960s, but there is no solid evidence of the evolution of penicillin resistance in yaws. The historical strategy for the eradication of yaws (1952–1964) was:
Sources: en.wikipedia.org
=== Different views on well-being === Various cultures have various perspectives on the nature of positive human functioning. For example, studies on aversion to happiness, or fear of happiness, indicates that some individuals and cultures are averse to the experience of happiness, because they believe happiness may cause bad things to happen. Empirical evidence indicates that there are fundamental differences in the ways well-being is construed in Western and non-Western cultures, including the Islamic and East Asian cultures. Exploring various cultural perspectives on well-being, Joshanloo (2014) identifies and discusses six broad differences between Western and non-Western conceptions of well-being. For example, whereas Western cultures tend to emphasize the absence of negative emotions and autonomy in defining well-being, Eastern cultures tend to emphasize virtuous or religious activity, self-transcendence, and harmony. Eunkook M. Suh (University of California) and Shigehiro Oishi (University of Chicago) examined the differences of happiness on an international level and different cultures' views on what creates well-being and happiness. In a study, of over 6,000 students from 43 nations, to identify mean life satisfaction, on a scale of 1–7, the Chinese ranked lowest at 3.3; and Dutch scored the highest at 5.4. When asked how much subjective well-being was ideal, Chinese ranked lowest at 4.5, and Brazilians highest at 6.2, on a scale of 1–7.
Sect. Andinium W.Becker (113) S America Sect. Chamaemelanium Ging. s.lat. (61) N America, northeast Asia (includes Dischidium, Orbiculares) Subsect. Chamaemelanium Subsect. Nudicaules Subsect. Nuttalianae Sect. Chilenium W.Becker (8) southern S America Sect. Danxiaviola W. B. Liao et Q. Fan (1) China Sect. Delphiniopsis W.Becker (3) western Eurasia: southern Spain; Balkans Sect. Erpetion (Banks) W.Becker (11–18) eastern Australia; Tasmania Sect. Leptidium Ging. (19) S America Sect. Melanium Ging. (125) western Eurasia (pansies) Sect. Nosphinium W.Becker s.lat. (31–50) N, C and northern S America; Beringia; Hawaii Sect. nov. A (V. abyssinica group) (1–3) Africa: equatorial high mountains Sect. nov. B (V. spathulata group) (7–9) western and central Asia: northern Iraq to Mongolia Sect. Plagiostigma Godr. (120) northern hemisphere (includes Diffusae) Grex Primulifolia Sect. Rubellium W.Becker (3–6) S America: Chile Sect. Sclerosium W.Becker (1–4) northeastern Africa to southwestern Asia Sect. Tridens W.Becker (2) southern S America Sect. Viola s.str. (Rostellatae nom. illeg.) (75) northern hemisphere (violets) (includes Repentes) Subsect. Rostratae Kupffer (W.Becker) Subsect. Viola Sect. Xylinosium W.Becker (3–4) Mediterranean region
Traditional non-alcoholic beverage companies, like PepsiCo, Fuze Beverage, and The Coca-Cola Company. Major food companies, such as Nestlé, Altria, Kraft Foods, General Mills, and the Campbell Soup Company. Smaller-scaled private companies and specialized companies like POM Wonderful. Agricultural cooperatives, such as Ocean Spray and Sunsweet Growers.
Yet the party wanted a Concordat not least because of the massive intimidation to which it had been subjected since the end of February 1933. This included violent attacks on Centre Party meetings during campaigning for the elections of 5 March 1933, during one of which the Centre Party politician and former government minister Adam Stegerwald was severely beaten by Nazi stormtroopers (on 22 February). One after another in the spring and early summer of 1933, Catholic lay organisations were being forcibly closed down or merged with their Nazi counterparts, Catholic journalists and newspaper editors were arrested, especially if they had attacked the Nazi-led coalition government in print, and leading Catholics were brutally mistreated by the SA. (...) Not surprisingly, it was fear of the complete destruction of its lay organisations and the reversal of all the progress that Catholic laymen had made towards gaining equality of status with Protestants that provided the major impetus behind the agreement of the Centre to dissolve itself in return for a Concordat in which the new regime would commit itself – with how little sincerity would soon become apparent – to preserving the integrity of the Catholic community and its institutions. A considerable number of parliamentarians opposed the chairman's course, among these former Chancellors Heinrich Brüning, Joseph Wirth and former minister Adam Stegerwald.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.